Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 3 April 2023 Vol. No. 12; Issue No. 572

1. Kamtalwar S, Mirgh S, More A, Gokarn A, Dhumal S, Sharma P, Lall S, Patkar N, Shetty N, Chatterjee G, Rajpal S, Bhat V, Khattry N, Gupta S (2023). Triple trouble: Disseminated Penicilliosis in a cancer patient with COVID-19. Indian Journal of Medical and Paediatric Oncology.

2. Butti R, Kapse P, Bhadauriya G, Ahmad S, Chaubal R, Parab P, Kadam R, Mahapatra SS, Shet T, Dutt A, Gupta S, Kundu GC(2023). Development and characterization of a patient derived orthotopic xenograft of therapy resistant breast cancer. Oncology Reports. 49(5): 99.

Site of the Week

GeneWise compares a protein sequence to a genomic DNA sequence, allowing for introns and frameshifting errors.

desktop Image
Interesting Reads

Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhen R, Weinberg AD, Spencer CN, Ng D, He XY, Albrengues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 186(7):1432-1447.e17, 2023.

Legends of Science
Srinivasa Rangaswami Srinivasa Rangaswami

Srinivasa Rangaswami obtained his PhD from the Andhra University in 1938. He did pioneering work on chemistry of wood rotting fungi and complicated structure of saponins. He explained the structure of several novel steroidal and triterpinoidal substances. He discovered a potent cardiotonic drug, Peruvoside. He served in the advisory committees like Pharmacy Council of India, Drug Technical Advisory Board, Indian Pharmacopoeia Committee. Dr. Rangaswami was an elected fellow of the Indian Academy of Sciences, Bangalore; Indian Chemical Society; Royal Society of Chemistry; Indian Pharmaceutical Association.

Vinayak Govind Panse Vinayak Govind Panse

Vinayak Govind Panse obtained his PhD from the University of London, UK in 1940. He developed a method of crop-cutting surveys for improving the statistics of acreage and yield of other principal crops. With his success in the development of replicated progeny and compact family block designs, he made significant contribution to the statistical methods in quantitative genetics. He came out with yardsticks to assess the progress of agriculture in each state of the country. Dr. Panse was the elected secretary of the Indian Society of Agricultural Statistics.

Upcoming Events
11th European Congress on Breast Cancer, Women's Health and Therapeutics

27-29 April, 2023

At Amsterdam,Netherlands.

Basic Mechanisms to Clinical Trials in Brain Tumors

25-30 June, 2023

At Bryant University, Smithfield, United States.

Global Meet on Oncology and Cancer Research

29-30 June, 2023

At Rome, Italy

Do You Know?

In 1945, Felix Bloch and Edward Purcell discovered nuclear magnetic resonance, used today to detect brain tumors and other cancers.

back Image
Cancer News
Tata Memorial starts 24/7 post-chemo helpline unit

28 March 2023, Times of India

Tata Memorial Hospital, the central government's cancer care hub in Parel, has started a 24 by 7 "after chemo" helpline for patients who undergo chemotherapy sessions on an outpatient basis. At present, TMH gets 65,000 new cancer patients and conducts 4.5 lakh follow-ups annually...

Researchers design a microfluidics physics based device to predict cancer therapy response

31 March 2023, MedicalXpress

Researchers have designed a microfluidic device called microfluidic dynamic BH3 profiling (μDBP) that predicts the effectiveness of cancer treatment quickly and automatically, using a small number of cells from biopsies and without requiring specialized technical staff...

Combination therapy a promising option for advanced kidney cancer patients already treated with immunotherapy

31 March 2023, EurekAlert

Researchers investigated for the first time the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor. Belzutifan has shown antitumor activity and favorable safety in heavily pretreated advanced kidney cancer...

2023 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)